An FDA-approved biosimilar to Neulasta® (pegfilgrastim)[1]*

NYVEPRIA™ (pegfilgrastim-apgf) product and reimbursement information for your practice

Not actual size.

NYVEPRIA Injection for Subcutaneous Use

Ordering NYVEPRIA—What You Need to Know[1]	
Unit of Sale	6 mg/0.6 mL
Unit of Sale NDC	0069-0324-01
Unit of Sale Quantity	1 prefilled syringe
Unit of Sale List Price†	$3,925
HCPCS Code[2]	**Descriptor**
Q5122	Injection, pegfilgrastim-apgf, biosimilar, (NYVEPRIA), 0.5 mg

*Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar and the reference product.[1]
†As of May 2021.

340B pass-through status effective April 1, 2021[2]

IMPORTANT SAFETY INFORMATION

Contraindications

- NYVEPRIA is contraindicated in patients with a history of serious allergic reactions to pegfilgrastim products or filgrastim products
- Reactions have included anaphylaxis

(CONTINUED ON NEXT PAGE)

Please see Important Safety Information and Indication throughout and full Prescribing Information, Patient Information, and Instructions for Use available at NyvepriaHCP.com.

INJECTION
Nyvepria™
pegfilgrastim-apgf
Pfizer

IMPORTANT SAFETY INFORMATION (CONTINUED)

Warnings and Precautions

Splenic Rupture

- Splenic rupture, including fatal cases, can occur following the administration of pegfilgrastim products
- Evaluate for an enlarged spleen or splenic rupture in patients who report left upper abdominal or shoulder pain after receiving NYVEPRIA

Acute Respiratory Distress Syndrome (ARDS)

- ARDS can occur in patients receiving pegfilgrastim products
- Evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving NYVEPRIA
- Discontinue NYVEPRIA in patients with ARDS

Serious Allergic Reactions

- Serious allergic reactions, including anaphylaxis, can occur in patients receiving pegfilgrastim products
- The majority of reported events occurred upon initial exposure
- Allergic reactions, including anaphylaxis, can recur within days after the discontinuation of initial anti-allergic treatment
- Permanently discontinue NYVEPRIA in patients with serious allergic reactions
- Do not administer NYVEPRIA to patients with a history of serious allergic reactions to pegfilgrastim products or filgrastim products

Use in Patients with Sickle Cell Disorders

- Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving pegfilgrastim products
- Discontinue NYVEPRIA if sickle cell crisis occurs

Glomerulonephritis

- Glomerulonephritis has occurred in patients receiving pegfilgrastim products
- The diagnoses were based on azotemia, hematuria (microscopic and macroscopic), proteinuria, and renal biopsy
- Generally, events of glomerulonephritis resolved after dose-reduction or discontinuation of pegfilgrastim products
- If glomerulonephritis is suspected, evaluate for cause. If causality is likely, consider dose-reduction or interruption of NYVEPRIA

(CONTINUED ON NEXT PAGE)

IMPORTANT SAFETY INFORMATION (CONTINUED)

Warnings and Precautions (continued)

Leukocytosis

- White blood cell counts of 100 x 10^9/L or greater have been observed in patients receiving pegfilgrastim products
- Monitoring of complete blood count (CBC) during NYVEPRIA therapy is recommended

Thrombocytopenia

- Thrombocytopenia has been reported in patients receiving pegfilgrastim products
- Monitor platelet counts

Capillary Leak Syndrome (CLS)

- CLS has been reported after granulocyte-colony stimulating factor (G-CSF) administration, including pegfilgrastim products, and is characterized by hypotension, hypoalbuminemia, edema, and hemoconcentration
- Episodes vary in frequency and severity and may be life-threatening if treatment is delayed
- Patients who develop symptoms of CLS should be closely monitored and receive standard symptomatic treatment, which may include a need for intensive care

Potential for Tumor Growth Stimulatory Effects on Malignant Cells

- The G-CSF receptor through which pegfilgrastim and filgrastim products act has been found on tumor cell lines
- The possibility that pegfilgrastim products act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which pegfilgrastim products are not approved, cannot be excluded

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) in Patients with Breast and Lung Cancer

- MDS and AML have been associated with the use of pegfilgrastim products in conjunction with chemotherapy and/or radiotherapy in patients with breast and lung cancer
- Monitor patients for signs and symptoms of MDS/AML in these settings

Aortitis

- Aortitis has been reported in patients receiving pegfilgrastim products. It may occur as early as the first week after start of therapy
- Manifestations may include generalized signs and symptoms such as fever, abdominal pain, malaise, back pain, and increased inflammatory markers (eg, c-reactive protein and white blood cell count)
- Consider aortitis in patients who develop these signs and symptoms without known etiology. Discontinue NYVEPRIA if aortitis is suspected

(CONTINUED ON NEXT PAGE)

IMPORTANT SAFETY INFORMATION (CONTINUED)

Warnings and Precautions (continued)

Nuclear Imaging

- Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone imaging changes. This should be considered when interpreting bone imaging results

Most Common Adverse Reactions

- Bone pain
- Pain in extremity

INDICATION

NYVEPRIA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Limitations of Use

NYVEPRIA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

NYVEPRIA Payer Coverage Nationwide



71%
of Medicare lives covered, including managed Medicare[3*†]

41%
of commercially insured patients have access to NYVEPRIA nationwide[3*†]

*As of May 2021.
†The information provided in this communication is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures. Nothing herein may be construed as an endorsement, approval, recommendation, representation, or warranty of any kind by any plan or insurer.



FOR LIVE, PERSONALIZED SUPPORT
Call **1-877-744-5675** (Monday–Friday 8 AM–9 PM ET)

VISIT
PfizerOncologyTogether.com

References: 1. NYVEPRIA [prescribing information]. New York, NY: Pfizer Inc.; April 2021. **2.** Centers for Medicare & Medicaid Services. April 2021 HCPCS Quarterly Update. Updated April 1, 2021. **3.** Data on file. Pfizer Inc.; New York, NY.

Please see Important Safety Information and Indication throughout and full Prescribing Information, Patient Information, and Instructions for Use available at NyvepriaHCP.com.

